Lung Carcinoma Clinical Trials

89 recruitingLast updated: June 17, 2026

There are 89 actively recruiting lung carcinoma clinical trials across 44 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1. Top locations include Houston, Texas, United States, Barcelona, Spain, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Lung Carcinoma Trials at a Glance

89 actively recruiting trials for lung carcinoma are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Phase 2 with 27 trials, with the heaviest enrollment activity in Houston, Barcelona, and Boston. Lead sponsors running lung carcinoma studies include M.D. Anderson Cancer Center, Mayo Clinic, and Memorial Sloan Kettering Cancer Center.

Browse lung carcinoma trials by phase

Treatments under study

About Lung Carcinoma Clinical Trials

Looking for clinical trials for Lung Carcinoma? There are currently 28 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 89 trials

Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 3

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Small Cell Lung Carcinoma
AstraZeneca70 enrolled15 locationsNCT06992609
Recruiting
Phase 1Phase 2

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Small Cell Lung CancerSmall Cell Lung Carcinoma
Memorial Sloan Kettering Cancer Center53 enrolled1 locationNCT04199741
Recruiting
Phase 1Phase 2

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled102 locationsNCT06772623
Recruiting
Not Applicable

CONNECTing to LungCare

Lung CarcinomaSmoking CessationCigarette Smoking-Related Carcinoma
University of California, San Francisco152 enrolled1 locationNCT06213532
Recruiting
Phase 1Phase 2

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled22 locationsNCT07407933
Recruiting
Not Applicable

A Study of Hospital-at-Home for People Receiving Tarlatamab

Small Cell Lung CancerSmall Cell Lung Carcinoma
Memorial Sloan Kettering Cancer Center70 enrolled7 locationsNCT06957314
Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Breast CarcinomaEsophageal CarcinomaHead and Neck Carcinoma+6 more
M.D. Anderson Cancer Center5,000 enrolled1 locationNCT00991094
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 2

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Lung CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+10 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04789681
Recruiting
Phase 2

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Lung CancerBrain Metastases, AdultBrain Metastases+3 more
Memorial Sloan Kettering Cancer Center62 enrolled7 locationsNCT05419076
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled15 locationsNCT06463665
Recruiting

Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

Non-Small Cell Lung Carcinoma (NSCLC)
University of Malaya150 enrolled4 locationsNCT07369596
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Non-small Cell Lung CancerNSCLCMetastatic Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)665 enrolled17 locationsNCT06917079
Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals44 enrolled10 locationsNCT05703516
Recruiting
Not Applicable

New York Better Breathing Study

Stage III Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Localized Lung Carcinoma+1 more
Roswell Park Cancer Institute100 enrolled1 locationNCT06869447
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Non-small Cell Lung CancerNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Revolution Medicines, Inc.590 enrolled143 locationsNCT06881784
Recruiting
Not Applicable

Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking

Lung CarcinomaTobacco-Related Carcinoma
Ronald Myers822 enrolled1 locationNCT05679349